Search

Your search keyword '"Eating disorders -- Drug therapy"' showing total 3 results
Start Over Descriptor "Eating disorders -- Drug therapy" Journal plus company updates
3 results on '"Eating disorders -- Drug therapy"'

1. Tonix Pharmaceuticals Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity

Subjects
United States. Food and Drug Administration, Eating disorders -- Drug therapy, Obesity in children -- Drug therapy, Prader-Willi syndrome -- Drug therapy, Drug approval, Clinical trials, General interest, News, opinion and commentary
Abstract

CHATHAM, N.J: Tonix Pharmaceuticals Holding Corp. has issued the following news release: Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, [...]

Published
2023

3. Saniona's partner Medix submits new drug application in Mexico for tesofensine in obesity

Subjects
Obesity -- Drug therapy, Eating disorders -- Drug therapy, Drug approval, Biotechnology, Biotechnology industries, General interest, News, opinion and commentary
Abstract

Ballerup: Saniona AB has issued the following press release: Saniona (OMX: SANION), a clinical stage biotech company focused on eating disorders and CNS, today announced that its partner Medix has [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results